Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 6/20 | 0.60 |
| ▸ | CPB1 | P15086 | 1/20 | 0.51 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 3/20 | 0.50 |
| ▸ | MMP9 | P14780 | 3/20 | 0.50 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.49 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.48 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP3 | P08254 | 1/20 | 0.47 |
| ▸ | MMP7 | P09237 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8211666 | 0.83 | FOLH1 (0.68) | FOLH1MMP2MMP9 | |
| SCHEMBL20510519 | 0.83 | FOLH1 (0.68) | FOLH1MMP2MMP9 | |
| SCHEMBL8211672 | 0.83 | FOLH1 (0.56) | FOLH1SIRT2SIRT1SIRT3 | |
| SCHEMBL15844493 | 0.83 | FOLH1 (0.68) | FOLH1MMP2MMP9 | |
| SCHEMBL25418512 | 0.82 | FOLH1 (0.67) | FOLH1MMP2MMP9 | |
| SCHEMBL31314039 | 0.82 | FOLH1 (0.67) | FOLH1MMP2MMP9 | |
| SCHEMBL234108 | 0.81 | HTT (0.64) | FOLH1SIRT2SIRT1SIRT3 | |
| SCHEMBL19975584 | 0.80 | FOLH1 (0.36) | FOLH1CPB2 | |
| SCHEMBL21032736 | 0.79 | FOLH1 (0.51) | FOLH1 | |
| SCHEMBL8119521 | 0.79 | FOLH1 (0.69) | FOLH1CPB1CPB2MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10617662-B2 | Autophagy activation-induced compound for improving skin inflammation for aging | INCOSPHARM CORPORATION (KR) | 2020-04-14 | — | — | US | disclosed |
| US-20190160033-A1 | NOVEL AUTOPHAGY ACTIVATION-INDUCED COMPOUND FOR IMPROVING SKIN INFLAMMATION FOR AGING | INCOSPHARM CORPORATION (KR) | 2019-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10617662-B2 | Autophagy activation-induced compound for improving skin inflammation for aging | TFEB, ATG7, BECN1 | FOLH1 4203/4885CPB1 3564/4885CPB2 2220/4885 |
| US-20190160033-A1 | NOVEL AUTOPHAGY ACTIVATION-INDUCED COMPOUND FOR IMPROVING SKIN INFLAMMATION FOR AGING | TFEB, ATG7, BECN1 | FOLH1 3707/4885CPB1 3548/4885CPB2 2261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.